Sol-Gel Technologies (SLGL) Interest Expenses (2016 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Interest Expenses of $58.5 million for Q4 2025, up 17.5% year-over-year from $49.8 million in Q4 2024, and up 15418.3% quarter-over-quarter from $377000.0 in Q2 2025.
Sol-Gel Technologies (SLGL) Interest Expenses (2016 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Interest Expenses for 10 consecutive years, with $58.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses rose 17.5% year-over-year to $58.5 million; the TTM figure through Mar 2026 stood at $377000.0 (up 18.18% YoY), while the FY2025 annual figure was $58.5 million, up 17.5% from the prior year.
- Interest Expenses improved to $58.5 million in Q4 2025 per SLGL's latest filing, from $377000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $58.5 million in Q4 2025 and bottomed at $319000.0 in Q2 2024.
- Historically, Interest Expenses has averaged $28.9 million across 5 years, with a median of $44.7 million in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 10854.41% — and 2024, when it gained 3.92%.
- Sol-Gel Technologies' Interest Expenses stood at $408000.0 in 2021, then jumped by 10854.41% to $44.7 million in 2022, then climbed by 7.2% to $47.9 million in 2023, then advanced by 3.92% to $49.8 million in 2024, then gained by 17.5% to $58.5 million in 2025.
- Business Quant data shows SLGL's Interest Expenses at $58.5 million in Q4 2025, $377000.0 in Q2 2025, and $49.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.50 Mn |
| Dec 31, 2025 | 58.50 Mn |
| Jun 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 377,000.00 |
| Dec 31, 2024 | 49.79 Mn |
| Dec 31, 2024 | 49.79 Mn |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Dec 31, 2023 | 47.91 Mn |
| Dec 31, 2023 | 47.91 Mn |
| Dec 31, 2022 | 44.69 Mn |
| Dec 31, 2022 | 44.69 Mn |
| Dec 31, 2021 | 408,000.00 |
| Dec 31, 2021 | 408,000.00 |
| Dec 31, 2020 | 374,000.00 |
| Dec 31, 2020 | 374,000.00 |
| Dec 31, 2019 | 308,000.00 |
| Dec 31, 2019 | 308,000.00 |
| Jun 30, 2019 | 912,000.00 |
| Jun 30, 2019 | 912,000.00 |